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aclitaxel Versus Sirolimus
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hristodoulos Stefanadis, MD, FACC,
onstantinos Toutouzas, MD
thens, Greece
rug-eluting stents (DES) have proven to be superior to
are-metal stents in several randomized trials in terms of
ngiographic restenosis rate and the incidence of major
dverse cardiac events, although they are associated with an
ncreased late thrombosis rate. These important findings
hanged interventional cardiology, as more complex proce-
ures are being performed. We have to keep in mind that
hese essential data have arisen from large randomized trials,
n which the safety and efficacy of the first-generation DES
as investigated. The primary efficacy end point was the
ngiographic restenosis rate, and indeed both the sirolimus-
luting stent (SES) and the paclitaxel-eluting stent (PES)
roved to be effective (1–4). These randomized trials really
hanged the field of interventional cardiology, and thus SES
nd PES are the most widely used DES to date.
See page 658
Thereafter the question emerged: Which stent is associated
ith better safety and efficacy? Randomized trials for head-to-
ead comparison of SES and PES were performed and have
hown clearly that: 1) there is no difference in the incidence of
eath and cardiac death; and 2) PES are associated with more
ate loss compared with SES (5,6); furthermore, in one study
he angiographic restenosis rate was greater in the PES group
6.6% vs. 11.7%, p  0.02) (6).
Registries have definite advantages and disadvantages.
hey can provide significant information regarding the
eal-life clinical practice, and thus evaluate the clinical
pplication of several therapeutic strategies. The evaluation
owever of the safety and the efficacy of 2 or 3 different
pproaches is extrapolated, because the interference of the
eterogeneity of protocols, subjects, and entry criteria in the
nal results cannot be completely abolished. These are
mportant reasons for the usual failure of registries and
eta-analyses to predict the outcomes of large randomized
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thet
merican College of Cardiology.
From the Department of Cardiology, Athens Medical School, Athens, Greece.linical trials. Thus, the conclusions of the mentioned large
egistry contribute significantly to our knowledge, but these
esults need to be considered under the prism of the
entioned methodological limitations (7).
Post-hoc meta-analyses and registries have been used to
ompare the safety and efficacy of these 2 most widely used
ES. In this issue of the Journal, Kaltolft et al. (7) report
he results of the Western Denmark Heart Registry, and
onclude that during a 2-year follow-up period, PES are
ssociated with increased mortality because of an increased
ate of myocardial infarction after 12 months of follow-up.
oreover, they mention that the clinically driven target lesion
evascularization rates were similar between SES and PES.
The excess of mortality rate in the PES group has not
een confirmed by previous randomized trials. The recent
nalysis of the pivotal blinded, randomized, controlled trials
f both PES and SES did not show any difference in the
ncidence of definite or probable stent thrombosis occurring
to 4 years after the procedure using the Academic
esearch Consortium (8). These results are in accordance
ith the recently reported rate of stent thrombosis of the
ORT OUT II (Danish Organization on Randomized
rials With Clinical Outcome) randomized trial performed
n Denmark (9). Thus, the lower incidence of stent throm-
osis in the SES group can be attributed to differences in the
aseline demographic characteristics. Indeed, more patients
ith acute coronary syndromes were treated with PES. In
ddition, the baseline comorbidity index score was higher in
he PES group (Table 1) (7). Another shortcoming is the
etrospective application of the new definitions of stent
hrombosis. The increased rate of myocardial infarction
annot be exclusively attributed to stent thrombosis, as the
uthors also mention in the Discussion. Finally, the designed
ength of double antiplatelet therapy and related compliance
or individual patients were not strictly followed.
Similar limitations possibly led to the controversial results of
nother larger registry. In the first report of the SCAAR
Swedish Coronary Angiography and Angioplasty Registry),
ES were associated with an increased rate of death and
yocardial infarction compared with bare-metal stents (10).
he inclusion of more patients with a longer follow-up period
howed no difference in mortality or myocardial infarction (11).
re All DES Equal?
here are several differences in the stent design, the poly-
er, and the drug eluted in the DES. Whether these
ifferences have an impact in the clinical outcome of the
reated patients has not been confirmed in large prospective
linical trials with the statistical power to identify differences
n the rate of stent thrombosis and myocardial infarction.
he most important contribution of large registries is to
onfirm that the current practice, as established by the
andomized trials, is indeed in the right direction. The
esults of the Western Denmark Heart Registry confirmed
hat DES are associated with a lower need for target lesion
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Paclitaxel Versus Sirolimus February 24, 2009:665–6evascularization compared with bare-metal stents, without
n accompanied increase in mortality (7).
The progress of DES is substantial, and several new
latforms with new drugs are being tested. The new PES
Liberte vs. Express, Boston Scientific Corp., Natick, Mas-
achusetts) in more complex lesions (Taxus Atlas Small
essel and Long Lesion) was associated with a noninferior
afety profile and a reduced rate of myocardial infarction
12). These results were also confirmed by the subgroup
nalysis of the SCAAR study (11).
Despite the differences in the technical characteristics be-
ween the currently available stents, we need large randomized
rials adequately powered to reveal differences in the clinical
nd points. The DES are still the primary tool for preventing
estenosis, and we expect that the advancement of technology
ill soon resolve the drawbacks of currently available stents.
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